LAUSANNE, SWITZERLAND – Novigenix, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, recently announced the appointment of Dr Pedro Romero, MD, PhD as its Chief Medical & Scientific Officer. Dr. Romero has previously served as Director of Medical & Scientific Affairs and on the Medical Advisory Board of Novigenix.
In his new role as Chief Medical & Scientific Officer of Novigenix, Dr. Romero brings over three decades of experience in immunology and immune-oncology expertise to the team. He has previously served as Deputy Scientific Director of the Lausanne branch of the Ludwig Institute for Cancer Research in Switzerland and in 2021 was made Honorary Professor of the University of Lausanne. He is a specialist in translational tumor immunology and immunotherapy of cancer as well as immune and tumoral responses.
“As the Chief Medical Officer & Scientific Officer at Novigenix, I am delighted and honoured to have the opportunity to lead our dedicated team towards further advancements in medical innovation”, said Dr. Romero. “Building upon the foundation laid by our ImmunoTranscriptomics platform, I am committed to driving excellence in clinical strategy and medical affairs, with a steadfast focus on improving patient outcomes and revolutionizing the landscape of therapeutic modalities. Together, we will continue to harness the power of data-driven insights to redefine the standard of care and positively impact the lives of patients worldwide through development of novel therapeutics.“
For over a decade, Novigenix has demonstrated leadership in bringing precision immunology to the market, integrating multi-omics data with AI through its proprietary LITOSeek™ platform. This innovative approach offers insights into patient immune responses for early detection of cancer and precision development of novel therapeutics.
